Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    AstraZeneca: Don’t Buy Us

    After Pfizer’s less-than-wonderful earnings report yesterday, AstraZeneca is out today painting a picture of how great things will be if they don’t get swallowed by them. John Carroll at FierceBiotech has the details, but I especially enjoyed his pithy comment on Twitter: “AZN made more promises today than I will ever see broken a… Read More
  • Business and Markets

    Fast Money, But What Direction Is It Going?

    If you’re inclined to get your financial info from fast-talking analysts on cable news channels, you might want to give this blog post a read. The author points out several egregious mistakes that CNBC’s “Fast Money” has made with biotech/pharma stocks by having traders giving out advice and forecasts despite apparently know… Read More
  • Business and Markets

    Pfizer/AstraZeneca: Asymmetric Cuts Look Likely

    So Pfizer is out today with some pretty bad financials, which are doubtless one reason for their determination to Go Out and Buy Somebody, whether they’re an R&D powerhouse or not. They’ve also been reassuring the British government that they’ll go ahead with the Cambridge research construction that AstraZeneca has begun, and… Read More
  • Business and Markets

    Some People at Pfizer Whose Fault This Isn’t

    It’s worth keeping in mind, as the Pfizer/AZ story develops, that there are some people that don’t get mentioned who aren’t enjoying this, either: the scientists in Pfizer’s labs. As I’ve mentioned, I know folks there, and I know that there are (still) an awful lot of good scientists working there. And they, of course… Read More
  • Business and Markets

    Allergan: “Golf-Course Deprived”

    Here’s a good one for you. Valeant is well-known as an outfit that largely scorns R&D, and cuts it whenever they buy someone. They do mergers and acquisitions to get the fruits of someone else’s research instead. You know, sort of a mini-Pfizer. (If anyone at Pfizer is offended by that comparison, they should take… Read More
  • Business and Markets

    AstraZeneca Tell Pfizer to Buzz Off

    That’s what I gather from this report, anyway. Reports had leaked out that Pfizer was going to make a higher offer for AZ shares, and that happened earlier this morning. But AstraZeneca’s board has turned it down flat, saying that it undervalues the company and “is not an adequate basis” for further discussions. You’d… Read More
  • Business and Markets

    Can Anything Stop Pfizer-AstraZeneca From Going Through?

    At FierceBiotech, John Carroll asks the question that’s on a lot of drug-industry minds this week: can anything stop Pfizer’s takeover of AstraZeneca? There are a few possibilities, but overall, it comes down to how much money Pfizer wants to spend. If they open their wallet far enough, they can buy most anyone they want. Read More
  • Business and Markets

    Concert’s First Drug: Not So Great

    Concert Pharmaceuticals, famous among medicinal chemists as the apparent leaders in the “deuterated drug” strategy, has reported clinical trial results for their lead compound, CTP-499. Unfortunately, it missed its primary endpoint of improving albumin/creatinine ratios in patients. There are some signs that it might be doing some good… Read More
  • Business and Markets

    Pfizer and AstraZeneca: What the Hell.

    What the hell is Ian Read thinking? Pfizer is apparently going hostile with their attempt to buy out AstraZeneca, all but ensuring that the deal, if it goes through, will take place at the highest price and in the messiest fashion that it possibly could. And for what? Update: Matthew Herper asks the same question… Read More
  • Business and Markets

    Ycombinator Gets Into Biotech

    Here’s an article from Nature News on the startup incubator company Ycombinator moving into biotech funding. Those of you familiar with them will wonder a bit about this, because it’s a space that they’ve avoided. But read on: In 2008, Y Combinator founder Paul Graham wrote that funding biotechnology start-ups was too expensive. W… Read More
...293031...